leadf
logo-loader
viewHorizon Discovery Group PLC

Horizon Discovery's board member steps down

Dr David Smoller has left the company by a mutual agreement.

empt_boardroom,_sized_5644adf06925b.png
Smoller will leave to pursue other business interests, Horizon said.

Horizon Discovery (LON:HZD) announced its chief business officer and executive director Dr David Smoller has left the company.

He joined in September 2014 as part of Horizon’s acquisition of Sage Labs and has stepped down by mutual agreement.

With Sage now successfully integrated into the company, Smoller will now leave to pursue other business interests, Horizon said.

Dr. Ian Gilham, chairman of Horizon, said Smoller has “assisted with the rapid integration of Sage Labs into the Horizon group and continued revenue growth of our services business.”

Horizon specialises in drug discovery and personalised medicine, supplying research tools to research organisations developing new medicines.

Quick facts: Horizon Discovery Group PLC

Price: 187 GBX

AIM:HZD
Market: AIM
Market Cap: £295.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Horizon Discovery Group PLC named herein, including the promotion by the Company of Horizon Discovery Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Horizon Discovery's CareDx partnership validates model

Horizon Discovery Group PLC (LON:HZD) says its continued collaboration with CareDx Inc validates its model. Horizon makes cell lines, which can be used to stand in for real patient samples, and firms which are developing assays and research tools, can utilise them. The latest agreement is...

on 11/09/2016

2 min read